BioMarin

BioMarin is a global biotechnology firm founded in 1997, specializing in the development and commercialization of therapies for rare, genetically defined diseases. The company focuses on enzyme replacement and specialized treatments for conditions such as mucopolysaccharidosis, phenylketonuria, achondroplasia, severe hemophilia A, and Batten disease. Its diverse product portfolio includes Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, Aldurazyme, and Roctavian. Meet BioMarin's team to understand the leadership driving these scientific advancements.

Operating with 1,000-5,000 employees, BioMarin maintains a robust operational footprint with nine global locations. The company manages sophisticated manufacturing facilities in the United States and Ireland to support its global distribution network. Learn about BioMarin's global headquarters for detailed information regarding their geographic presence and operational infrastructure. The firm continues to leverage its expertise in metabolic science to pioneer new therapeutic pathways, maintaining a competitive edge against industry peers like Biogen and Gilead Sciences.

BioMarin demonstrates significant market presence with annual revenue of $3.4B. As a publicly traded entity on the NASDAQ under the ticker BMRN, the company remains committed to delivering equitable healthcare solutions through integrated biopharmaceutical discovery. Explore financial highlights to review detailed metrics, funding history, and fiscal performance. By focusing on high-impact rare disease treatments, BioMarin sustains its position as a leader in the biotechnology sector, consistently investing in pipeline development to address unmet medical needs globally.